drugset / Trial / NCT06876129

Pharmacologic Augmentation of TMS for Depression With D-serine

NCT06876129

Phase 1 Recruiting 60 enrolled Mclean Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this study is to test whether combining D-serine with 30 treatments of a) iTBS and b) 18-Hz protocols will enhance clinical outcomes compared to rTMS with placebo (i.e., sugar pill). The investigators hypothesize that NMDA receptor activation via D-serine combined with repeated sessions of rTMS will produce greater clinical outcomes than iTBS with placebo and 18-Hz with placebo.

Timeline

Start
2025-04-01
Primary completion
2026-12-26
Completion
2027-04-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator D-serine Unknown 80 mg/kg Oral

Indications